[Inhibition of platelet aggregation and thromboxane formation by the calcium antagonist nisoldipine following a single oral dose of 10 mg. A double-blind study in healthy probands].
The influence of the calcium antagonist nisoldipine on collagen-induced platelet aggregation and platelet thromboxane formation was studied ex vivo in healthy male volunteers in a double-blind, placebo-controlled crossover design. Measurements of general haemodynamics, immunoreactive 6-oxo-prostaglandin F1 alpha and thromboxane B2 ex vivo and collagen-induced (0.6 and 2.5 micrograms/ml) platelet aggregation were performed immediately before (time 0), 0.5 h, 1 h and 2 h after ingestion of 10 mg nisoldipine or an identical placebo tablet. Compared with the control response at time 0, administration of nisoldipine resulted in a significant inhibition of both low-collagen-induced platelet aggregation and formation of immunoreactive thromboxane B2 at time 0.5 h. There were no changes in heart rate or systolic blood pressure but a significant decrease in diastolic blood pressure by nisoldipine at 1 h. No such change was obtained with placebo and there were also no alterations with nisoldipine in platelet aggregation and thromboxane formation after stimulation by high-dose collagen at this or any other time of the study. The data demonstrate a platelet-inhibitory potential of nisoldipine in healthy men which is probably related to an increased resistance of the platelet membrane against foreign stimuli.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000284:Administration, Oral; D000328:Adult; D001792:Blood Platelets / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000097:blood / Q000494:pharmacology*; D004311:Double-Blind Method; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D009543:Nifedipine / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D015737:Nisoldipine; D010974:Platelet Aggregation / Q000187:drug effects*; D013929:Thromboxane B2 / Q000494:pharmacology*; D013931:Thromboxanes / Q000494:pharmacology*
D002121:Calcium Channel Blockers; D013931:Thromboxanes; D015737:Nisoldipine; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D009543:Nifedipine
Hemmung der Plättchenaggregation und Thromboxanbildung durch den Calcium-Antagonisten Nisoldipin nach einer oralen Einmaldosis von 10 mg. Eine Doppelblind-Crossover-Studie bei gesunden Probanden.